Merck and Ridgeback Biotherapeutics have started a Phase 3 trial (MOVe-NOW) to assess LAGEVRIO™ (molnupiravir) in treating COVID-19 among high-risk adults.

IMFINZI® (durvalumab) has been authorized in the US as the first and sole immunotherapy treatment for patients with limited-stage small cell lung cancer.

Elritercept is an advanced investigational activin inhibitor aimed at treating anemia linked with specific hematologic malignancies.

Arrowhead Pharmaceuticals Seeks Approval to Start Phase 1/2a Trial of ARO-ALK7 for Obesity Treatment.

Jasper Therapeutics has reported the initial patient receiving treatment in the Phase 1b/2a ETESIAN trial of Briquilimab for asthma.

Epsilogen has declared the initiation of a Phase Ib trial assessing MOv18 IgE in individuals suffering from platinum-resistant ovarian cancer (PROC).

OncoC4 has received FDA approval for its IND application regarding AI-081, a promising PD-1/VEGF bispecific therapy for advanced solid tumors.

TORL BioTherapeutics has named Aran Maree, M.D., as its Chief Medical Officer and has begun a Phase 2 study for TORL-1-23.

Spyre Therapeutics Reports First Dosing of Participants in Phase 1 Trials for New Extended Half-Life Anti-TL1A Antibodies.

The U.S. FDA has given the green light to Biocon Biologics' biosimilar YESINTEK™, Bmab 1200, which is comparable to J&J's Stelara® (Ustekinumab).

In modern gene therapy, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are key nucleic acid drugs that offer new treatment options for genetic and complex diseases.

Alector reveals findings from the AL002 INVOKE-2 Phase 2 study on early Alzheimer’s disease and shares company updates.